The Huntsman Cancer Institute at the University of Utah has treated the first three patients in a phase I first-in-human clinical trial of RYZ401, an investigational actinium-225 (AC-225)-based radiopharmaceutical targeting somatostatin receptors in neuroendocrine tumors (NETs) and other solid tumors.
RYZ401 combines a novel peptide with Ac-225, which emits alpha particles to deliver a high-energy dose over a short distance, according to the sponsor. The trial is sponsored by RayzeBio, a Bristol Myers Squibb company, and is evaluating RYZ401's safety, tolerability, and early efficacy in patients with advanced NETs or other somatostatin receptor-expressing cancers.
The study is led by Heloisa Soares, MD, PhD, medical director of theranostics at the Huntsman Cancer Institute and associate professor of internal medicine at the University of Utah. The trial is currently enrolling.
